Gentian Diagnostics ASA Logo

Gentian Diagnostics ASA

Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.

GENT | OL

Overview

Corporate Details

ISIN(s):
NO0010748866
LEI:
5967007LIEEXZXHNM861
Country:
Norway
Address:
Bjørnåsveien 5, 1596 Moss
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gentian Diagnostics ASA is a global developer and manufacturer of in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for major clinical chemistry platforms, aiming to enhance diagnostic efficiency for laboratories. Its product portfolio addresses high-value biomarkers for both human and veterinary medicine, with a focus on kidney disease, cardiac disease, inflammation, and infection. By developing innovative and efficient diagnostic tests, Gentian enables laboratories to reduce costs and deliver faster, more accurate results to support better treatment decisions. The company serves the global market through a network of OEM partners, distributors, and healthcare providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 08:11
Investor Presentation
Gentian Diagnostics presents at the Pareto Securities Healthcare conference - A…
English 1.3 MB
2025-09-16 08:11
Report Publication Announcement
Gentian Diagnostics presents at the Pareto Securities Healthcare conference
English 683 bytes
2025-07-10 08:00
Interim Report
Gentian Diagnostics: Second quarter 2025 report - Attachment: GDASA Interim re…
English 859.1 KB
2025-07-10 08:00
Investor Presentation
Gentian Diagnostics: Second quarter 2025 report - Attachment: GDASA Q2 25 pres…
English 2.2 MB
2025-07-10 08:00
Earnings Release
Gentian Diagnostics: Second quarter 2025 report
English 2.7 KB
2025-07-03 13:22
Report Publication Announcement
Gentian Diagnostics: Invitation to presentation of second quarter results
English 721 bytes
2025-06-02 16:34
Major Shareholding Notification
Flaggemelding Gentian Diagnostics ASA
Norwegian 495 bytes
2025-05-23 09:39
Major Shareholding Notification
Disclosure of shareholding
English 986 bytes
2025-05-22 08:47
Major Shareholding Notification
Disclosure of large shareholding
English 893 bytes
2025-05-08 08:00
Director's Dealing
Mandatory notification of trade
Norwegian 131.6 KB
2025-05-08 08:00
Major Shareholding Notification
Mandatory notification of trade
English 1.4 KB
2025-05-07 06:07
Notice of Dividend Amount
Gentian Diagnostics: Ex dividend NOK 0.40 today
English 708 bytes
2025-05-07 06:00
Investor Presentation
Gentian Diagnostics: First quarter 2025 report
English 2.1 MB
2025-05-07 06:00
Earnings Release
Gentian Diagnostics: First quarter 2025 report
English 750.7 KB
2025-05-07 06:00
Earnings Release
Gentian Diagnostics: First quarter 2025 report
English 2.7 KB

Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.